Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12618001476224
Ethics application status
Approved
Date submitted
18/07/2018
Date registered
4/09/2018
Date last updated
6/08/2019
Date data sharing statement initially provided
6/08/2019
Type of registration
Prospectively registered
Titles & IDs
Public title
Efficacy and safety of (a) A-Lfor Plasmodium falciparum and (b) P-A for Plasmodium falciparum and Plasmodium vivax malaria in Ta-mu Township, Sagaing Region
Query!
Scientific title
Study on clinical and parasitological outcome of (a) ACT, A-L for falciparum malaria and (b) P-A for falciparum and vivax malaria in Ta-mu township, Sagaing Region
Query!
Secondary ID [1]
295663
0
nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
nil
Query!
Linked study record
nil
Query!
Health condition
Health condition(s) or problem(s) studied:
malaria related fever
308882
0
Query!
headache
308883
0
Query!
ache
308884
0
Query!
mailaise
309100
0
Query!
loss of appetite
309101
0
Query!
Condition category
Condition code
Public Health
307793
307793
0
0
Query!
Other public health
Query!
Infection
307978
307978
0
0
Query!
Other infectious diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
a non-randomized control trial will be used having two arms of treatment regimes. One arm will be given artemether-lumefantrine (A-L)and another with pyronaridine-artesunate (P-A) for falciparum malaria. For vivax malaria only one arm, pyronaridine-artesunate will be administered.
All patients eligible for the study will be enrolled.The odd numbers will be treated with A-L, while the even numbers will be treated with P-A.
Each artemether-lumefantrine tablet consists as 20 mg : 120 mg respectively.
artemether-lumefantrine will be given as follows:
(a) Body weight having 5-14 Kg. one tablet twice a day for three days
(b) Body weight having 15-24 Kg. two tablets twice a day for three days
(c) Body weight having 24-35 Kg. three tablets twice a day for three days
(d) Body weight having 35 Kg and above: four tablets twice a day for three days
Each tablet of pyronaridine : artesunate composed as 180 mg and 60 mg respectivelt
Pyronaridine-artesunate will be given as follows:
(a) 15-19 Kg. body weight: half tablet once a day for three days
(b) 20-24 Kg. body weight: one tablet once a day for three days
(c) 25-44 Kg. body weight : two tablets once a day for three days
(d) 45-64 Kg. body weight: three tablets once a day for three days
(e) 65 Kg. and above: four tablets once a day for three days
All tablets will be given by oral administration
Query!
Intervention code [1]
301882
0
Treatment: Drugs
Query!
Comparator / control treatment
For falciparum malaria, currently using artemether-lumefantrine will be used as a control regime. There is no control drug for vivax malaria.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
306777
0
Adequate Clinical and Parasitological Response (ACPR)
Blood smears will be taken on days 1,2,3,7,14,21,and 28 days after the initial treatment.
Each follow-up will consist of clinical assessment, body temperature and microscopic examination of Giemsa stained thick blood smear
(Tympanic temperature will be assessed by using digital thermometer to a one decimal number))
( malaria parasites will be identified and counted by Giemsa stained thick smear microscopic examination. Two qualified laboratory technicians will check the blood smears. If the difference between the two reading results are more than 10%, third reader will be invited for confirmation of the findings.).
Query!
Assessment method [1]
306777
0
Query!
Timepoint [1]
306777
0
28 days from enrollment
Query!
Primary outcome [2]
306974
0
Early Treatment Failure (ETF)
If the patient have severe signs and symptoms of malaria within three days of initial treatment
(or) Fever persist after three days of treatment (Tympanic temperature will be assessed by using digital thermometer to a one decimal number))
(or) Malaria asexual parasites remain after three days of treatment ( malaria parasites will be identified and counted by Giemsa stained thick smear microscopic examination. Two qualified laboratory technicians will check the blood smears. If the difference between the two reading results are more than 10%, third reader will be invited for confirmation of the findings.).
Query!
Assessment method [2]
306974
0
Query!
Timepoint [2]
306974
0
Three days after initial treatment
Query!
Secondary outcome [1]
349595
0
Late Treatment Failure (LTF)
It is assessed after 4-28 days of treatment by
(a) General conditions.
Medical officer will perform clinical examination: level of consciousness, inspection of anemia (pallor) , measuring heart rate, respiration, blood pressure . He will ask if there is presence of vomiting, diarrhea or other illness.
(b) Body temperature assessment(Tympanic temperature will be assessed by using digital thermometer to a one decimal number))
(c) Asexual malaria parasites counting by microscopic examination of Giemsa stained thick blood smear..( malaria parasites will be identified and counted by Giemsa stained thick smear microscopic examination. Two qualified laboratory technicians will check the blood smears. If the difference between the two reading results are more than 10%, third reader will be invited for confirmation of the findings.).
Query!
Assessment method [1]
349595
0
Query!
Timepoint [1]
349595
0
4-28 days after the initial treatment
Query!
Eligibility
Key inclusion criteria
Patients having fever with a parasitological count of more than 1000 asexual parasites per 1 ul of blood for P.falciparum malaria and 500 asexual parasites per 1 ul for P. vivax malaria
Query!
Minimum age
6
Years
Query!
Query!
Maximum age
60
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients having severe and complicated malaria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
P.falciparum malaria will be treated with either AL (or) P-A, while all P.vivax malaria patients will be treated with P=A.
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Number of minimum patients needed to be calculated according to the WHO therapeutic efficacy treatment guidelines.
Data obtained will be entered, cleaned and analyzed according to the Standard excel template developed by WHO.
Query!
Recruitment
Recruitment status
Withdrawn
Query!
Reason for early stopping/withdrawal
Lack of funding/staff/facilities
Query!
Date of first participant enrolment
Anticipated
1/10/2018
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
31/12/2018
Query!
Actual
Query!
Date of last data collection
Anticipated
31/01/2019
Query!
Actual
Query!
Sample size
Target
50
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
10727
0
Myanmar
Query!
State/province [1]
10727
0
Sagaing Region
Query!
Funding & Sponsors
Funding source category [1]
300161
0
Other Collaborative groups
Query!
Name [1]
300161
0
World Health Organization
Query!
Address [1]
300161
0
No. 4013 A, Shwe Taung Kyar Street
Bahan Township
Yangon Region
MYANMAR
Query!
Country [1]
300161
0
Myanmar
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
WHO country office
Query!
Address
No. 403 A,
Shwe Taung Kyar Street,
Bahan Township,
YANGON Region
MYANMAR
Query!
Country
Myanmar
Query!
Secondary sponsor category [1]
299568
0
None
Query!
Name [1]
299568
0
nil
Query!
Address [1]
299568
0
nil
Query!
Country [1]
299568
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
300993
0
Ethics Review Committee, Department of Medical Research
Query!
Ethics committee address [1]
300993
0
Department of Medical Research
No.5, Ziwaka Road,
Dagon Township,
YANGON 11191
MYANMAR
Query!
Ethics committee country [1]
300993
0
Myanmar
Query!
Date submitted for ethics approval [1]
300993
0
22/02/2018
Query!
Approval date [1]
300993
0
12/04/2018
Query!
Ethics approval number [1]
300993
0
002716
Query!
Summary
Brief summary
The study will be done in Ta-mu township, Sagaing Region which is located in the norther-west part of the country along the Myanmar-India border.
It is regarded as the sentinel site by WHO to monitor the drug resistance malaria in the region as there is a lot of population migration along the two countries. The activity of monitoring the drug resistance malaria has been started since 2009 in this area.
In 2018, the study is intended to start in the September where clinically suspected malaria patients will be tested using Giemsa stained microscopic examination. Patients having asexual malaria parasites 1000 per micro-liter and above will be enrolled and given either artemether-lumefantrine or pyronaridine-artesuante regimes, which are the standard ACTs and regarded as standard regimes by the Ministry of Health and Sports. The patients will be followed up on days 2,3 and every week up to for 28 days for artemether-lumefantrine group (or) 42 days for those treated with pyronaridine-artesunate regime. The clinical symptoms will also be recorded during the visits and blood will be tested by microscopic examination as well as by filter papers for PCR test. Then findings will be classified as
(a) Adequate Clinical and Parasitological Resonse (ACPR) (b) Early Treatment Failure or (c) Late Treatment Failure according to the WHO guidelines.
Query!
Trial website
Query!
Trial related presentations / publications
nil
Query!
Public notes
nil
Query!
Contacts
Principal investigator
Name
85534
0
Dr KHIN LIN
Query!
Address
85534
0
Department of Medical Research
Ward No. (10), Pyin Oo Lwin township
Mandalay Region
MYANMAR
Query!
Country
85534
0
Myanmar
Query!
Phone
85534
0
095-0943151627
Query!
Fax
85534
0
095-8520-50251
Query!
Email
85534
0
[email protected]
Query!
Contact person for public queries
Name
85535
0
Dr KHIN LIN
Query!
Address
85535
0
Department of Medical Research
Ward No. (10), Pyin Oo Lwin township
Mandalay Region
MYANMAR
Query!
Country
85535
0
Myanmar
Query!
Phone
85535
0
095-08520-50436
Query!
Fax
85535
0
095-8520-50251
Query!
Email
85535
0
[email protected]
Query!
Contact person for scientific queries
Name
85536
0
Dr KHIN LIN
Query!
Address
85536
0
Department of Medical Research
Ward No. (10), Pyin Oo Lwin township
Mandalay Region
MYANMAR
Query!
Country
85536
0
Myanmar
Query!
Phone
85536
0
095-08520-50436
Query!
Fax
85536
0
095-8520-50251
Query!
Email
85536
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF